Boan Biotech Nears Denosumab Registration After Phase III Enrollment Completion

Biosimilar Developer Is Nearing The Finish Line As Key Patents Are Set To Expire In 2025

 
• By Urtė Fultinavičiūtė

Completion of the Phase III trial may lead Boan Biotech to international registrations of denosumab, a market worth over $5.6bn globally.

Two People Participating In A Clinical Trial
Boan Biotech’s denosumab biosimilar BA6101 is already approved in China • Source: Shutterstock

More from Biosimilars

More from Products